Respironics contributes $4 million to sleep research
MURRYSVILLE, Pa. - Respironics reached new heights in fiscal year 2007, with sales jumping 14% to $1.2 billion, the company reported July 25. That annual total includes a 17% ($21 million) bump in revenues from domestic sleep therapy products.
Highlights from the company's 2007 and fourth-quarter financial results include the following:
-- Net sales for the fourth quarter totaled $332.4 million, about 18% more than the same quarter last year.
-- Domestic revenues increased from $196.9 million in the fourth quarter a year ago to $224.8 million this year, a 14% increase.
-- Home respiratory care revenues jumped 19% to $3.3 million in the fourth quarter.
-- Globally, sleep therapy revenues grew by 21% in the fourth quarter.
-- The company contributed $4 million to the Respironics Sleep and Respiratory Research Foundation, which was established to increase education, awareness and advance basic research in the fields of sleep and respiratory medicine. The fourth quarter contribution is earmarked for a multi-year trial of patients with obstructive sleep apnea who are also at increased cardiovascular risk. The trial, which will be conducted in India, China and Australia, will evaluate the effect of CPAP therapy on cardiovascular outcomes for individuals suffering from OSA.